Design, Synthesis, and Biological Activity of Novel 1,3,5-Triazine-1,2,4-Triazine Hybrids as Cholinesterase Inhibitors

被引:1
|
作者
Dong, Chang-E. [1 ,2 ]
Li, Rui [1 ,2 ]
Pan, Zai-Xiu [1 ,2 ]
Li, He [1 ,2 ]
Qian, Jing-Jing [1 ,2 ]
Liu, Wei-Wei [1 ,2 ,3 ]
Cao, Zhi-Ling [1 ,2 ,3 ]
Shi, Da-Hua [1 ,2 ,3 ]
机构
[1] Jiangsu Ocean Univ, Jiangsu Key Lab Marine Biotechnol, Jiangsu Key Lab Marine Bioresources & Environm, Lianyungang 222005, Peoples R China
[2] Jiangsu Ocean Univ, Sch Pharm, Lianyungang 222005, Peoples R China
[3] Coinnovat Ctr Jiangsu Marine Bioind Technol, Lianyungang 222005, Peoples R China
关键词
Alzheimer disease; acetylcholinesterase; butyrylcholinesterase; 1,3,5-triazine; 1,2,4-triazine; TRIAZINE DERIVATIVES; ACETYLCHOLINESTERASE;
D O I
10.1134/S1070428023090191
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
Fourteen 1,3,5-triazine-1,2,4-triazine hybrids were designed and synthesized. Their structures were confirmed by IR, NMR, and high-resolution mass spectra, as well as by single crystal X-ray diffraction. The cholinesterase inhibitory activities of the hybrids were assayed by Ellman's method. Five of the fourteen hybrids inhibited acetylcholinesterase by more than 50% at a concentration of 50 mu M. Only two hybrids inhibited butyrylcholinesterase by more than 50% at a concentration of 50 mu M. Compound 5c possessed the best acetyl-cholinesterase and butyrylcholinesterase inhibitory activities with IC50 of 6.80 +/- 0.14 mu M and 1.91 +/- 0.12 mu M, respectively. Molecular docking showed that compound 5c interacted with both catalytic active site and peripheral anionic site of acetylcholinesterase.
引用
收藏
页码:1610 / 1619
页数:10
相关论文
共 50 条
  • [1] Design, Synthesis, and Biological Activity of Novel 1,3,5-Triazine–1,2,4-Triazine Hybrids as Cholinesterase Inhibitors
    Chang-E. Dong
    Rui Li
    Zai-Xiu Pan
    He Li
    Jing-Jing Qian
    Wei-Wei Liu
    Zhi-Ling Cao
    Da-Hua Shi
    Russian Journal of Organic Chemistry, 2023, 59 : 1610 - 1619
  • [2] Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity
    Dao, Pascal
    Lietha, Daniel
    Etheve-Quelquejeu, Melanie
    Garbay, Christiane
    Chen, Huixiong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (08) : 1727 - 1730
  • [3] SYNTHESIS OF 1,2,4-TRIAZINE
    PAUDLER, WW
    BARTON, JM
    JOURNAL OF ORGANIC CHEMISTRY, 1966, 31 (06): : 1720 - &
  • [4] Design, synthesis and biological evaluation of quinoline-1,2,4-triazine hybrids as antimalarial agents
    Feng, Yuan-Yuan
    Dong, Chang-E
    Li, Rui
    Zhang, Xiao-Qing
    Wang, Wei
    Zhang, Xing-Rui
    Liu, Wei -Wei
    Shi, Da-Hua
    JOURNAL OF MOLECULAR STRUCTURE, 2023, 1271
  • [5] Synthesis, characterization and biological activity of some 1,2,4-triazine derivatives
    El-Barbary, AA
    Sakran, MA
    El-Madani, AM
    Nielsen, C
    JOURNAL OF HETEROCYCLIC CHEMISTRY, 2005, 42 (05) : 935 - 941
  • [6] POLY(1,3,5-TRIAZINE)S AND POLY(1,2,4-TRIAZINE)S
    WAHL, B
    WOHRLE, D
    MAKROMOLEKULARE CHEMIE-MACROMOLECULAR CHEMISTRY AND PHYSICS, 1975, 176 (04): : 849 - 858
  • [7] Synthesis and characterization of novel 1,2,4-triazine derivatives with antiproliferative activity
    Krauth, Fabian
    Dahse, Hans-Martin
    Ruettinger, Hans-Hermann
    Frohberg, Petra
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (05) : 1816 - 1821
  • [8] Synthesis and antiviral activity of 1,2,4-triazine derivatives
    V. L. Rusinov
    I. N. Egorov
    O. N. Chupakhin
    E. F. Belanov
    N. I. Bormotov
    O. A. Serova
    Pharmaceutical Chemistry Journal, 2012, 45 : 655 - 659
  • [9] SYNTHESIS AND ANTIVIRAL ACTIVITY OF 1,2,4-TRIAZINE DERIVATIVES
    Rusinov, V. L.
    Egorov, I. N.
    Chupakhin, O. N.
    Belanov, E. F.
    Bormotov, N. I.
    Serova, O. A.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2012, 45 (11) : 655 - 659
  • [10] Xanthone-1,2,4-triazine and Acridone-1,2,4-triazine Conjugates: Synthesis and Anticancer Activity
    Santra, Sougata
    Sharapov, Ainur D.
    Fatykhov, Ramil F.
    Potapova, Anastasya P.
    Khalymbadzha, Igor A.
    Valieva, Maria I.
    Kopchuk, Dmitry S.
    Zyryanov, Grigory V.
    Bunev, Alexander S.
    Melekhin, Vsevolod V.
    Gaviko, Vasiliy S.
    Zonov, Andrey A.
    PHARMACEUTICALS, 2023, 16 (03)